Acute coronary patients undergoing coronary artery bypass surgery.. Chronic ischemic heart disease, unspecified
Conditions
Interventions
Intervention 1: Intervention group: Patients in the DEX group, after transfer to the operating room and initial preparation, receive an initial dose (bolus) of dexmedetomidine at a rate of 0.5 µg/kg b
Sponsors
Shahid Rajaee Cardiovascular Educational, Research and Treatment Institute
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: The inclusion criteria for this study are designed to study a target population with similar and controllable physiologic and hemodynamic conditions under a single treatment protocol. The inclusion criteria are as follows:1. Patient age:o Patients aged 18 years and above are accepted in this study. This age restriction is to ensure safety and compatibility of the patient's condition with the pharmacological properties of dexmedetomidine, as well as to control for variables related to adult physiology.2. Stable hemodynamic status:o Only patients with stable cardiac output before and during surgery are included in the study. This condition ensures that the effect of the drug is evaluated only in patients with similar baseline hemodynamic status and that the results are not confounded by differences due to unstable conditions.3. Informed Consent:o After patients are fully informed about the aims, methods, expected outcomes, and possible risks of the study, written consent will be obtained from them. Patient awareness of the study and obtaining informed consent, as one of the ethical principles of clinical research, will be part of the patient entry process.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Antioxidant capacity. Timepoint: For antioxidant capacity, blood samples will be collected from patients at three different time points: preoperatively, immediately after the end of surgery, and 12 hours after surgery in the ICU. Method of measurement: Each sample, consisting of 5 ml of arterial blood, is carefully processed to prevent the destruction of antioxidant markers. The samples are centrifuged at 500–1000 g for 30 min at room temperature, and the serum is then separated. TAC is measured using kits from Zellbio (Germany, GmbH) and according to the manufacturer's instructions.;Hemodynamic variables. Timepoint: Hemodynamic variables such as heart rate, systolic and diastolic blood pressure will be recorded at various time points, including preoperatively, immediately after induction of anesthesia, after cardiopulmonary bypass, and at intervals of 2, 4, 6, and 24 hours after admission to the ICU. Method of measurement: It will be measured by a sphygmomanometer and pulse oximetry device. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHossein kalantari
Shahid Rajaee Cardiovascular Educational, Research and Treatment Institute
Outcome results
None listed